Rosiglitazone for type 2 diabetes mellitus (Q24243875)

2

E

Bandeira-Echtler

1 reference

30 October 2023

Karla Bergerhoff

3

K

Bergerhoff

1 reference

30 October 2023

Christine Clar

4

C

Clar

1 reference

30 October 2023

Susanne H Ebrahim

5

S H

Cochrane Database of Systematic Reviews

Ebrahim

1 reference

30 October 2023

18 July 2007

0 references

published in

0 references

cites work

Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Thiazolidinediones for initial treatment of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Addition of Rosiglitazone to Existing Sulfonylurea Treatment in Chinese Patients with Type 2 Diabetes and Exposure to Hepatitis B or C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Meglitinide analogues for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Hyperglycemia and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Second-generation thiazolidinediones and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Analysis and reporting of factorial trials: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Hepatic injury in a patient taking rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Progress with thiazolidinediones in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Dietary advice for the prevention of type 2 diabetes mellitus in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Inhaled insulin in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Performance of an NIDDM screening questionnaire based on symptoms and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Diabetes, TZDs, and Bone: A Review of the Clinical Evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Glucagon-like peptide analogues for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Liver failure in a patient receiving rosiglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Misleading funnel plot for detection of bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Publication bias in meta-analysis: its causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

21 January 2018

Rosiglitazone/Metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006063.PUB2

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report

1 reference

12 December 2020

Design, analysis and presentation of factorial randomised controlled trials

1 reference

12 December 2020

Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus

1 reference

12 December 2020

Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men

1 reference

12 December 2020

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus

1 reference

12 December 2020

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

1 reference

12 December 2020

Inhaled insulin in diabetes mellitus.

1 reference

12 December 2020

Rosiglitazone in the management of older patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control

1 reference

12 December 2020

Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes

1 reference

12 December 2020

'Human' insulin versus animal insulin in people with diabetes mellitus

1 reference

12 December 2020

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

1 reference

12 December 2020

Glycemic durability of monotherapy for diabetes

1 reference

12 December 2020

Dietary advice for treatment of type 2 diabetes mellitus in adults

1 reference

12 December 2020

Rosiglitazone and cardiovascular risk

1 reference

12 December 2020

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

1 reference

12 December 2020

Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.

1 reference

12 December 2020

1 reference

12 December 2020

Pioglitazone for type 2 diabetes mellitus

1 reference

12 December 2020

Report of the expert committee on the diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women

1 reference

12 December 2020

Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes.

1 reference

12 December 2020

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

1 reference

12 December 2020

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

10.1002/14651858.CD006063.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3125016

Fatcat ID

release_aaypgnlelnfc7jgtijbkmchsw4

0 references

OpenCitations bibliographic resource ID

3125016

1 reference